NOTICE -- Login operations are currently offline due to an unscheduled disruption. We are waiting for LDAP services to be re-instated. We apologize for the inconvenience - June 24, 2021
James Crowe
Faculty Member
Last active: 3/31/2020

  1. Vaccine innovations for emerging infectious diseases-a symposium report. Cable J, Srikantiah P, Crowe JE, Pulendran B, Hill A, Ginsberg A, Koff W, Mathew A, Ng T, Jansen K, Glenn G, Permar S, Wilson I, Weiner DB, Weissman D, Rappuoli R (2020) Ann N Y Acad Sci 1462(1): 14-26
    › Primary publication · 31659752 (PubMed)
  2. Multi-state design of flexible proteins predicts sequences optimal for conformational change. Sauer MF, Sevy AM, Crowe JE, Meiler J (2020) PLoS Comput Biol 16(2): e1007339
    › Primary publication · 32032348 (PubMed) · PMC7032724 (PubMed Central)
  3. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. Zhao H, Xu L, Bombardi R, Nargi R, Deng Z, Errico JM, Nelson CA, Dowd KA, Pierson TC, Crowe JE, Diamond MS, Fremont DH (2020) J Exp Med 217(2)
    › Primary publication · 31757867 (PubMed) · PMC7041715 (PubMed Central)
  4. E. coli production process yields stable dengue 1 virus-sized particles (VSPs). Hirsch J, Faber BW, Crowe JE, Verstrepen B, Cornelissen G (2020) Vaccine 38(17): 3305-3312
    › Primary publication · 32197924 (PubMed)
  5. Correction: Tissue-Specific Expressed Antibody Variable Gene Repertoires. Briney BS, Willis JR, Finn JA, McKinney BA, Crowe JE (2020) PLoS One 15(1): e0228412
    › Primary publication · 31978140 (PubMed) · PMC6980481 (PubMed Central)
  6. Broad dengue neutralization in mosquitoes expressing an engineered antibody. Buchman A, Gamez S, Li M, Antoshechkin I, Li HH, Wang HW, Chen CH, Klein MJ, Duchemin JB, Crowe JE, Paradkar PN, Akbari OS (2020) PLoS Pathog 16(1): e1008103
    › Primary publication · 31945137 (PubMed) · PMC6964813 (PubMed Central)
  7. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Gilchuk P, Murin CD, Milligan JC, Cross RW, Mire CE, Ilinykh PA, Huang K, Kuzmina N, Altman PX, Hui S, Gunn BM, Bryan AL, Davidson E, Doranz BJ, Turner HL, Alkutkar T, Flinko R, Orlandi C, Carnahan R, Nargi R, Bombardi RG, Vodzak ME, Li S, Okoli A, Ibeawuchi M, Ohiaeri B, Lewis GK, Alter G, Bukreyev A, Saphire EO, Geisbert TW, Ward AB, Crowe JE (2020) Immunity 52(2): 388-403.e12
    › Primary publication · 32023489 (PubMed) · PMC7111202 (PubMed Central)
  8. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Zhu X, Turner HL, Lang S, McBride R, Bangaru S, Gilchuk IM, Yu W, Paulson JC, Crowe JE, Ward AB, Wilson IA (2019) Cell Host Microbe 26(6): 729-738.e4
    › Primary publication · 31757767 (PubMed) · PMC6908751 (PubMed Central)
  9. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, Bryan A, Davidson E, Doranz BJ, Kuhn RJ, Diamond MS, Crowe JE, Rossmann MG (2019) Proc Natl Acad Sci U S A 116(5): 1591-1596
    › Primary publication · 30642974 (PubMed) · PMC6358714 (PubMed Central)
  10. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein. Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE, Slifka MK, Fremont DH, Klimstra WB, Diamond MS (2019) Nat Microbiol 4(1): 187-197
    › Primary publication · 30455470 (PubMed) · PMC6294662 (PubMed Central)